• +1-646-491-9876
    • +91-20-67278686

    Search

    Tularaemia Pipeline Review H1 2017

    Tularaemia Pipeline Review H1 2017

    • Report Code ID: RW0001799265
    • Category Pharmaceuticals
    • No. of Pages 68
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Tularaemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

    Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

    Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tularaemia - Overview
    Tularaemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tularaemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tularaemia - Companies Involved in Therapeutics Development
    Aradigm Corp
    Arno Therapeutics Inc
    DynPort Vaccine Company LLC
    Emergent BioSolutions Inc
    EpiVax Inc
    Grifols SA
    Merck & Co Inc
    Tetraphase Pharmaceuticals Inc
    Tularaemia - Drug Profiles
    AR-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARD-3100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARD-3150 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ciprofloxacin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EV-035 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRI-011225 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-271 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tularaemia [strain A] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tularaemia [strain B] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tularaemia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tularemia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tularaemia - Dormant Projects
    Tularaemia - Discontinued Products
    Tularaemia - Product Development Milestones
    Featured News & Press Releases
    Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
    May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
    Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Tularaemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Tularaemia - Pipeline by Aradigm Corp, H1 2017
    Tularaemia - Pipeline by Arno Therapeutics Inc, H1 2017
    Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2017
    Tularaemia - Pipeline by Emergent BioSolutions Inc, H1 2017
    Tularaemia - Pipeline by EpiVax Inc, H1 2017
    Tularaemia - Pipeline by Grifols SA, H1 2017
    Tularaemia - Pipeline by Merck & Co Inc, H1 2017
    Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
    Tularaemia - Dormant Projects, H1 2017
    Tularaemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Tularaemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aradigm Corp
    Arno Therapeutics Inc
    DynPort Vaccine Company LLC
    Emergent BioSolutions Inc
    EpiVax Inc
    Grifols SA
    Merck & Co Inc
    Tetraphase Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//tularaemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tularaemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tularaemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments